Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis.
Tullio PalmeriniAntonio Giulio BrunoMauro GaspariniGiulia RizzelloHyo-Soo KimJeehoon KangKyung Woo ParkJoo-Yong HahnYoung Bin SongHyeon-Cheol GwonEun-Ho ChooMahn-Won ParkChan Joon KimKiyuk ChangThomas CuissetNevio TaglieriByeong-Keuk KimYangsoo JangElena NardiFrancesco SaiaMatheusz OrzalkiewiczFrancesco ChieteraGabriele GhettiNazzareno GalièGregg W StonePublished in: Circulation. Cardiovascular interventions (2022)
In low bleeding risk patients with acute coronary syndrome undergoing percutaneous coronary intervention, compared with 1-year of potent DAPT, antiplatelet therapy deescalation therapy after 1 to 3 months was associated with decreased mortality and major bleeding with similar rates of major adverse cardiovascular events.
Keyphrases
- antiplatelet therapy
- cardiovascular events
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- atrial fibrillation
- coronary artery bypass grafting
- cardiovascular disease
- coronary artery bypass
- emergency department
- heart failure
- stem cells
- adverse drug